Ethnicity modifies the association between functional microRNA polymorphisms and breast cancer risk: A HuGE meta-analysis

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 529-543

  Chen, Qiao Hui ^a   Wang, Qing Bing ^a   Zhang, Bei ^b  

^a The Central Hospital of Minhang District   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast cancer; Meta analysis; MicroRNA; Single nucleotide polymorphism

Indexed keywords

MICRORNA;

ALLELE; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CAUCASIAN; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MICRORNAS; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK;

EID: 84894485952     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1074-7     Document Type: Article

References (67)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. McCormack VA, Boffetta P. Today's lifestyles, tomorrow's cancers: trends in lifestyle risk factors for cancer in low-and middle-income countries. Ann Oncol. 2011;22:2349-57.
3. Stuckey A. Breast cancer: epidemiology and risk factors. Clin Obstet Gynecol. 2011;54:96-102.
4. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene. 2006;25:5898-905.
5. Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet. 2008;124:31-42.
6. Evans JP, Skrzynia C, Susswein L,HarlanM. Genetics and the young woman with breast cancer. Breast Dis. 2005;23:17-29.
7. Balmana J, Diez O, Rubio IT, Cardoso F. BRCA in breast cancer: ESMO clinical practice guidelines. Ann Oncol. 2011;22 Suppl 6:vi31-4.
8. Bartel DP.MicroRNAs: genomics, biogenesis,mechanism, and function. Cell. 2004;116:281-97.
9. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522-31.
10. FilipowiczW, Bhattacharyya SN, Sonenberg N.Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9:102-14.
11. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861-74.
12. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065-70.
13. Duan R, Pak C, Jin P. Single nucleotide polymorphism associated with mature mir-125a alters the processing of pri-mirna. Hum Mol Genet. 2007;16:1124-31.
14. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, et al. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008;105:7269-74.
15. Chen J, Tian W, Cai H, He H, Deng Y. (2012) Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 29:2527-2534
16. Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, et al. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast zcancer patients. Jpn J Clin Oncol. 2012;42:256-63.
17. Wang C, Gao C, Zhuang JL, Ding C, Wang Y (2012) A combined approach identifies three mRNAs that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7. J Cancer Res Clin Oncol 138:2127-2136
18. Zhao FL, Hu GD, Wang XF, Zhang XH, Zhang YK, et al. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. J Int Med Res. 2012;40:859-66.
19. Zhou X, Marian C, Makambi KH, Kosti O, Kallakury BV, et al. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PloS One. 2012;7:e39011.
20. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 2005;436:740-4.
21. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-8.
22. Esquela-Kerscher A, Slack FJ. OncomiRs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-69.
23. Qiu LX, He J, Wang MY, Zhang RX, Shi TY, et al. The association between common genetic variant of microRNA-146a and cancer susceptibility. Cytokine. 2011;56:695-8.
24. Xu W, Xu J, Liu S, Chen B, Wang X, et al. Effects of common polymorphisms rs11614913 in miR-196a2 and rs2910164 in miR-146a on cancer susceptibility: a meta-analysis. PloS One. 2011;6:e20471.
25. Wang AX, Xu B, Tong N, Chen SQ, Yang Y, et al. Meta-analysis confirms that a common G/C variant in the pre-miR-146a gene contributes to cancer susceptibility and that ethnicity, gender and smoking status are risk factors. Gen Mol Res: GMR. 2012;11:3051-62.
26. Wang F, Sun G, Zou Y, Fan L, Song B. Lack of association of miR-146a rs2910164 polymorphism with gastrointestinal cancers: evidence from 10206 subjects. PloS One. 2012;7:e39623.
27. Wang J, Bi J, Liu X, Li K, Di J, et al. Has-miR-146a polymorphism (rs2910164) and cancer risk: a meta-analysis of 19 case-control studies. Mol Biol Rep. 2012;39:4571-9.
28. Wang J, Wang Q, Liu H, Shao N, Tan B, et al. The association of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk: a meta-analysis of 32 studies. Mutagenesis. 2012;27:779-88.
29. Lian H, Wang L, Zhang J. Increased risk of breast cancer associated with cc genotype of has-miR-146a rs2910164 polymorphism in Europeans. PloS One. 2012;7:e31615.
30. Wang F, Sun G, Zou Y, Li Y, Hao L, et al. Association of microRNA-499 rs3746444 polymorphism with cancer risk: evidence from 7188 cases and 8548 controls. PloS One. 2012;7:e45042.
31. Wang L, Qian S, Zhi H, Zhang Y, Wang B, et al. The association between Hsa-miR-499t>c polymorphism and cancer risk: a metaanalysis. Gene. 2012;508:9-14.
32. Wang Y, Yang B, Ren X. Hsa-miR-499 polymorphism (rs3746444) and cancer risk: a meta-analysis of 17 case-control studies. Gene. 2012;509:267-72.
33. Qiu MT, Hu JW, Ding XX, Yang X, Zhang Z, et al. Hsa-miR-499 rs3746444 polymorphism contributes to cancer risk: a meta-analysis of 12 studies. PloS One. 2012;7:e50887.
34. da Costa BR, Cevallos M, Altman DG, Rutjes AW, Egger M. Uses and misuses of the strobe statement: bibliographic study. BMJ Open. 2011;1:e000048.
35. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21:1539-58.
36. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123-37.
37. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA : J Am Med Assoc. 2006;295:676-80.
38. Hoffman AE, Zheng T,Yi C, LeadererD,Weidhaas J, et al.MicroRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res. 2009;69:5970-7.
39. Hu Z, Liang J, Wang Z, Tian T, Zhou X, et al. Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat. 2009;30:79-84.
40. Catucci I, Yang R, Verderio P, Pizzamiglio S, Heesen L, et al. Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum Mutat. 2010;31:E1052-7.
41. Pastrello C, Polesel J, Della Puppa L, Viel A,Maestro R. Association between Hsa-miR-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients. Carcinogenesis. 2010;31:2124-6.
42. Yang R, Schlehe B, Hemminki K, Sutter C, Bugert P, et al. A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat. 2010;121:693-702.
43. Jedlinski DJ, Gabrovska PN,Weinstein SR, Smith RA, Griffiths LR. Single nucleotide polymorphism in Hsa-miR-196a-2 and breast cancer risk: a case control study. Twin ResHumGenetOff J Int Soc Twin Stud. 2011;14:417-21.
44. Zhang P (2011) Polymorphisms of microRNA and ESR1 genes and their association with triple negative breast cancer risk and prognosis. Ph.D. thesis, Beijing Union Medical College
45. Alshatwi AA, Shafi G, Hasan TN, Syed NA, Al-Hazzani AA, et al. Differential expression profile and genetic variants of microRNAs sequences in breast cancer patients. PloS One. 2012;7:e30049.
46. Catucci I,Verderio P, Pizzamiglio S, Bernard L, Dall'olioV, et al. The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians. Breast Cancer Res Treat. 2012;133:805-7.
47. Linhares JJ, Azevedo JrM, Siufi AA, de Carvalho CV,WolgienMD, et al. Evaluation of single nucleotide polymorphisms in microRNAs (Hsa-miR-196a2 rs11614913 C/T) from Brazilian women with breast cancer. BMC Med Genet. 2012;13:119.
48. Smith RA, JedlinskiDJ,Gabrovska PN,Weinstein SR,Haupt L, et al. A genetic variant located in miR-423 is associated with reduced breast cancer risk. Cancer Genomics Proteomics. 2012;9:115-8.
49. Zhang M, Jin M, Yu Y, Zhang S,Wu Y, et al. Associations of miRNA polymorphisms and female physiological characteristics with breast cancer risk in Chinese population. Eur J Cancer Care. 2012;21:274-80.
50. Chen T, Li Z, Yan J, Yang X, Salminen W. MicroRNA expression profiles distinguish the carcinogenic effects of riddelliine in rat liver. Mutagenesis. 2012;27:59-66.
51. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10:389-402.
52. Landi D, Gemignani F, Landi S. Role of variations within microRNA-binding sites in cancer. Mutagenesis. 2012;27:205-10.
53. Negrini M, Calin GA. Breast cancer metastasis: a microRNA story. Breast Cancer Res. 2008;10:203.
54. Teraoka SN, Bernstein JL, Reiner AS, Haile RW, Bernstein L, et al. Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study. Breast Cancer Res. 2011;13:R114.
55. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007;67:2456-68.
56. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673-7.
57. Chu H, Wang M, Shi D, Ma L, Zhang Z, et al. Hsa-miR-196a2 rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies. PloS One. 2011;6:e18108.
58. Gao LB, Bai P, Pan XM, Jia J, Li LJ, et al. The association between two polymorphisms in pre-miRNAs and breast cancer risk: a metaanalysis. Breast Cancer Res Treat. 2011;125:571-4.
59. Qiu LX, Wang Y, Xia ZG, Xi B, Mao C, et al. Mir-196a2c allele is a low-penetrant risk factor for cancer development. Cytokine. 2011;56:589-92.
60. Tian T, Xu Y, Dai J, Wu J, Shen H, et al. Functional polymorphisms in two pre-microRNAs and cancer risk: a meta-analysis. Int J Mol Epidemiol Genet. 2010;1:358-66.
61. Wang F,Ma YL, Zhang P, Yang JJ, Chen HQ, et al. A genetic variant in microRNA-196a2 is associated with increased cancer risk: a metaanalysis. Mol Biol Rep. 2012;39:269-75.
62. Garcia AI, Cox DG, Barjhoux L, Verny-Pierre C, Barnes D, et al. (2011) The rs2910164:G>c snp in the mir146a gene is not associated with breast cancer risk in brca1 and brca2 mutation carriers. Human Mutat 32:1004-1007
63. Zhong S, Chen Z, Xu J, Li W, Zhao J (2013) Pre-mir-27a rs895819 polymorphism and cancer risk: a meta-analysis. Mol Biol Rep 40:3181-3186
64. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 2007;67:11001-11.
65. Guttilla IK, White BA. Coordinate regulation of foxo1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 2009;284:23204-16.
66. Ma Y, Yu S, Zhao W, Lu Z, Chen J. MiR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting sprouty2. Cancer Lett. 2010;298:150-8.
67. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434-42.